ANZUP Mini ASM 2020: ANZUP Trial Update - The ENZAMET Trial (UroToday.com) The 2020 Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting (ASM) featured a session on ANZUP trial updates, including an update of the critical Phase III ENZAMET trial provided by Drs. Ian Davis, Arun Azad, and Lisa Horvath. Dr. Davis started by recapping the 2019 publication of ENZAMET. 1 This trial randomly assigned 1,125 metastatic hormone-sensitive prostate cancer (mHSPC) patients from March 31, 2014, to March 24, 2017: 562 in the non-steroidal anti-androgen and 563 in the enzalutamide arm. The trial schema is as follows: The treatment groups were well balanced for all important baseline factors. In the non-steroidal anti-androgen arm, 44% of patients were planned for early docetaxel, compared to 45% in the enzalutamide arm; 53% of patients in the non-steroidal anti-androgen arm were high volume metastatic burden compared to 52% in the enzalutamide arm. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen (PSA) progression-free survival, clinical progression-free survival, and adverse events. At the time of the first interim analysis (median follow-up of 33 months), there were 143 deaths in the non-steroidal anti-androgen arm compared to 102 deaths in the enzalutamide arm. Overall survival was significantly prolonged in the enzalutamide arm compared to the non-steroidal anti-androgen arm (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.52-0.86):